← Back to Home

Lonza Adds ADC Capacity as the Contract Manufacturing Battleground Shifts to More Complex Cancer Drugs

Antibody-drug conjugates are moving from an R&D hotspot to a manufacturing bottleneck; Lonza’s expanded collaboration with a U.S. drugmaker shows that the next round of competition is not only about molecular design, but also about who can produce them reliably.

By SURL BioNews

Competition in new cancer drugs is often described as a race over targets and clinical data. But when a drug candidate actually moves toward patients, another, less visible threshold comes into view: manufacturing. According to Fierce Pharma, Swiss pharmaceutical contract manufacturing giant Lonza has expanded its collaboration with a U.S. drugmaker to increase capacity for antibody-drug conjugates (ADCs), reflecting rising supply-chain pressure for this class of complex medicines.

The report did not disclose the name of the U.S. drugmaker, the contract value, the specific site, or the scale of added capacity, so the collaboration is currently better interpreted as an industry signal rather than a quantifiable expansion commitment. What is clear is that Lonza is putting more resources into ADCs, a class of drugs that combines the difficulties of biologics and chemical manufacturing, and is trying to position itself before demand rises rapidly.

The concept behind ADCs is not new: antibodies are used as guides to deliver highly toxic cytotoxic drugs through linkers near tumor cells, with the aim of increasing the selectivity of cancer-cell killing as much as possible. The difficulty is that the antibody, linker, payload, and drug-to-antibody ratio all affect quality and efficacy. During production, manufacturers also have to handle large-molecule purification, control of toxic small-molecule substances, consistency of conjugation reactions, sterile fill-finish, and other steps at the same time.

This is also why the ADC boom is not only pushing drugmakers to search for new targets, but also increasing the importance of CDMOs. For R&D companies, before advancing candidates into mid- to late-stage clinical development, they must first confirm that the process can be scaled up, batches can remain stable, and analytical methods can support regulatory review. For large pharmaceutical companies, outsourcing or collaborative manufacturing can reduce the risk of internal capacity being locked into a single technology route.

In recent years, Lonza has strengthened its positioning in biologics and specialized drug formats, and ADCs fit that strategy: they are not products that can be solved simply by adding reactors or production lines, but require a combination of cross-disciplinary engineering capabilities and quality systems. If this collaboration is implemented smoothly, Lonza will have a better chance of integrating antibody production, conjugation, and downstream manufacturing into a more complete service chain.

However, capacity expansion itself does not equal clinical success. ADC drugs may still face limits in safety, drug resistance, tumor selectivity, or indication positioning; the manufacturing side may also be constrained by raw-material supply, technology transfer, and the pace of regulatory inspections. What this news really reveals is that ADCs are no longer just a buzzword in laboratories and investor decks, but are approaching a test of industrialization capability.

References

  1. Fierce Pharma